Avoiding restorative proctocolectomy for colorectal cancer in patients with ulcerative colitis based on preoperative diagnosis involving p53 immunostaining: report of a case by unknown
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Sada et al. World Journal of Surgical Oncology  (2015) 13:123 
DOI 10.1186/s12957-015-0540-7CASE REPORT Open AccessAvoiding restorative proctocolectomy for
colorectal cancer in patients with ulcerative colitis
based on preoperative diagnosis involving p53
immunostaining: report of a case
Haruki Sada, Manabu Shimomura*, Takao Hinoi, Hiroyuki Egi, Koji Kawaguchi, Takuya Yano, Hiroaki Niitsu,
Yasufumi Saitou, Hiroyuki Sawada, Masashi Miguchi, Tomohiro Adachi and Hideki OhdanAbstract
The standard operation for colitic cancer in ulcerative colitis (UC) is restorative proctocolectomy; however, sporadic
colorectal cancer (CRC) can coincidentally arise in patients with UC and the optimal procedure remains controversial.
Therefore, it is crucial to preoperatively determine whether the CRC in UC is a sporadic or colitic cancer. We report a
case of avoiding proctocolectomy for sporadic CRC in a patient with UC based on preoperative diagnosis involving
p53 immunostaining. A 73-year-old man with CRC in UC had undergone sigmoid colectomy with lymphadenectomy
because of the submucosal deep invasion pathologically after endoscopic mucosal resection. The cancer was
diagnosed sporadic cancer preoperatively not only based on the endoscopic, clinical, and histological patterns but also
that the colon epithelium was unlikely to develop dysplasia as the circumference and unaffected UC mucosa did not
detect p53 protein overexpression. Recent reports have shown that the immunohistochemical detection of p53 protein
overexpression can be useful for a differential diagnosis and as a predictor of dysplasia and colitic cancer. The analysis
of p53 mutation status based on immunostaining of p53 protein expression in the unaffected UC mucosa can be
useful for the decision regarding a surgical procedure for CRC in patients with UC.
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Patients with chronic extensive ulcerative colitis (UC) are at
high risk for developing colorectal cancer (CRC) or dyspla-
sia, which is supposed to develop along an inflammation-
dysplasia-carcinoma sequence [1]. CRC in UC is a serious
complication that can be life-threatening. However, spor-
adic adenomas or adenocarcinomas can arise coinciden-
tally, especially in elderly patients with UC. Differential
diagnosis between colitic cancer and sporadic cancer is an
important issue in critical practice, because the treatment
method differs considerably between these conditions [2].
Although restorative proctocolectomy is recognized as the
standard procedure for colitic cancer, the optimal proced-
ure for sporadic CRC remains questionable and partial* Correspondence: manabus@fuga.ocn.ne.jp
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unless otherwise stated.resection can be adequate, as the functional quality of life
differs substantially between patients with and without
proctocolectomy. A recent report has shown that for CRC
in UC, restorative proctocolectomy could be avoided be-
cause of the diagnosis of sporadic cancer based on endo-
scopic and histological findings [3]. The differences
between colitic and sporadic cancer have been investigated
based on endoscopic, clinical, and histological findings
[2,4]. Even in such studies, clearly distinguishing sporadic
and colitic cancer is difficult. Additionally, the immunohis-
tochemical detection of p53 protein overexpression can be
useful for the differential diagnosis and as a predictor of
dysplasia and colitic cancer [5-7]. We herein report that,
for the first time, colon cancer in UC was resected partially
not only based on endoscopic, clinical, and histological
findings but also by detecting unaffected UC mucosa not
detecting p53 protein overexpression.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A 73-year-old man was referred to our hospital com-
plaining of having had bloody stools five to seven times/
day for 1 month. He had no noteworthy medical or fa-
milial history, including inflammatory bowel diseases.
Colonoscopy showed moderate mucosal inflammation
throughout the rectum to the sigmoid colon and mul-
tiple erosions from the sigmoid colon to the cecum. The
findings also included a well-circumscribed raised tumor,
which was revealed to have a type IV to VI pit pattern,
15 mm in diameter, in the sigmoid colon (Figure 1). Step
biopsying was performed at 18 points from the rectum
to the terminal ileum, there being no findings of dyspla-
sia lesions microscopically. The pathological findings re-
vealed UC Matts’ grades 3 to 4 in the rectum to the
sigmoid colon and Matts’ grades 1 to 2 in the left-sided
colon to the cecum. He was given mesalazine (2,400 mg/
day) as the initial medical treatment. Endoscopic muco-
sal resection was also performed to remove the sigmoid
colon tumor at 1 month after the initial diagnosis.
Histological examination showed a 15 × 10-mm well-
differentiated adenocarcinoma with submucosal deep
invasion (4,000 μm) that detect diffusely p53 protein
accumulation in immunostaining. There was no intra-
venous or lymphatic invasion microscopically, and theFigure 1 Initial endoscopic findings. Colonoscopy showed mild mucosa
moderate inflammation from the sigmoid colon to the rectum (C,D). The f
revealed to have a type IV to VI pit pattern, 15 mm in diameter, in the sigmhorizontal and vertical margins were negative. The cir-
cumference mucosa around the cancer lesion did not
show dysplasia, and the circumference and unaffected
UC mucosa were considered negative for the p53 pro-
tein overexpression because only a few weakly positive
cells were detected (Figure 2).
For this case, additional surgical resection with lymph-
adenectomy was required because of the submucosal deep
invasion. At 3 months after the initial diagnosis of UC, the
bloody stools had disappeared, and clinical improvement
was attained with mesalazine (3,600 mg/day) and prednis-
olone (15 mg/day). Also, an endoscopic examination
showed improvement and Matts’ grade was 2 to 3 in the
rectum to the sigmoid colon pathologically. We performed
laparoscopy-assisted sigmoid colon resection with lymph
node dissection. The decision to perform partial resection
was made for two reasons. First, the initial diagnosis was
sporadic cancer. Second, his UC was well controlled with
no precious history, and his colon was not likely to de-
velop dysplasia or colitic cancer. Sporadic cancer was diag-
nosed based on the distinction from colitic cancer: late
onset and short duration of UC clinically, no characteristic
endoscopic findings of colitic cancer, no poorly differenti-
ated adenocarcinoma or signet-ring cell carcinoma, and
no detection of dysplasia pathologically. In addition, hisl inflammation throughout the cecum to the left-sided colon (A,B) and
indings also included a well-circumscribed raised tumor, which was
oid colon (C).
Figure 2 Histopathological findings for the endoscopic resection on immunohistochemistry for p53 protein. (A) The cancer lesion shows
diffuse positivity on p53 immunostaining. (B) The boundary between cancer and circumference mucosa is shown. The circumference mucosa
adjoining to cancer does not show any dysplasia. Only a few weak positive cells are exhibited in the non-neoplasia mucosa.
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unaffected UC mucosa did not detect p53 protein overex-
pression, which has been reported a predictor of dysplasia
and colitic cancer within the next few years. The resected
specimen showed no residual carcinoma tissue at EMR
sites in the sigmoid colon. The examined 38 lymph nodes
showed no evidence of a metastatic carcinoma. The post-
operative clinical course was uneventful. We added
granulocytapheresis (GCAP) therapy at 1 week after
operation, in order to prevent the UC from getting
worse and to reduce the amount of steroids. One year
after the operation, there was no evidence of cancer
recurrence, and the UC was in the remission state
with only mesalazine (3,600 mg/day), that is, no ster-
oid therapy.
Discussion
We have shown the detection of p53 protein overexpres-
sion in unaffected UC mucosa to be valuable to the deci-
sion regarding a surgical procedure for CRC in patients
with UC. The p53 gene is a member of a family of tumor
suppressor genes, and inactivation of this protein plays a
crucial role in the emergence and further progression of a
multitude of human malignancies including carcinomas of
the colon and rectum [6]. Most colitis-associated CRC
undergoes an inflammation-dysplasia-carcinoma sequence,
as opposed to the sporadic CRC, which undergoes an
adenoma-carcinoma sequence [4]. There are various differ-
ences in the timing and frequency of molecular changes
between sporadic and colitic cancer. In colitic cancer, mu-
tations and a loss of heterozygosity of p53 gene are early
events in UC mucosa, often occurring before dysplasia is
detected. However, in sporadic cancer, p53 mutations are
relatively late events in the progression of adenocarcin-
omas [8,9]. Ullman and Itzkowitz reported that oxidativestress was likely to be involved in these differences. And re-
active oxygen and nitrogen species produced by inflamma-
tory cells could affect regulation of genes that encode
factors that prevent carcinogenesis, transcription factors,
or signaling proteins [10].
Two previous studies investigated the prevalence of a
p53 protein overexpression for immunohistochemistry
[11,12]. Diffuse pattern, wherein strongly positive cells
exist in most areas of the tubules, and nested pattern,
wherein moderate to strongly positive cells are aggre-
gated in restricted areas of the tubule, were presumed to
reflect mutant forms of p53 protein and were defined as
overexpression of p53 protein [11]. Regarding invasive
CRC, colitic cancer with UC was expressed in 90.9% and
100%, and sporadic cancer cases without UC in 54.5%
and 59.5%. Additionally, in low-grade dysplasia, the
prevalences were 12.6% and 71.4%, and in high-grade
dysplasia 80% and 100%, compared with 5.6% in spor-
adic adenomas with and without UC and 0% in non-
neoplastic UC mucosa even in the active phase. A fairly
wide range of overexpressed p53 prevalence in low-
grade dysplasia was observed. Sato et al. assessed that
these discrepancies might be due to the differences be-
tween antibodies and antigen retrieval methods. More-
over, the precise nature of low-grade dysplasia is still
controversial and low-grade dysplasia diagnosed histo-
logically can consist of heterogeneous lesions [11]. Thus,
p53 immunostaining was considered to be a helpful
method for making a precise differential diagnosis of
dysplasia, distinguishing it from atypical epithelium due
to inflammatory or regenerating changes and from spor-
adic adenomas, coincidentally complicating UC [11,12].
Also, Lashner et al. evaluated colonic biopsy specimens
in immunohistochemical staining defining positive for the
p53 mutation if more than 5% of the epithelial cells in a
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ing. And they found p53 mutations developed approxi-
mately 8 months before low-grade dysplasia, 26 months
before high-grade dysplasia, and 38 months before cancer.
In addition, patients who tested positive for p53 mutations
were more than four times as likely than p53-negative pa-
tients to have dysplasia or cancer [5]. Furthermore, Takaku
et al. have described that if histologically non-neoplastic-
appearing mucosa with p53 protein overexpression har-
bors p53 mutations, this may be an early warning sign for
UC patients at risk of developing carcinomas [6]. Thus,
the detection of p53 protein overexpression can be one of
the valuable complementary tests for surveillance [5].
It is of clinical importance that the p53 gene mutations
do not always coincide with p53 protein overexpression.
Of all the p53 mutations in human cancer, 80% are mis-
sense mutations that result in a prolonged half-life of the
mutant p53 protein, allowing their detection by immuno-
histochemistry. Stop codon or nonsense mutations consti-
tute less than 20% of p53 mutations in human tumors.
These mutations cause a shortened, unstable, or absent
p53 protein product resulting in a completely negative p53
expression [7,13]. Thus, single-strand conformation poly-
morphism and PCR currently are the most precise
methods for identifying p53 suppressor gene mutations
and a loss of heterozygosity; however, these types of ana-
lyses are too expensive and time-consuming for routine
use in cancer surveillance. In contrast, immunohistochem-
istry is much less expensive and is technically easy and
monoclonal antibodies are readily available [5]. For these
reasons, many previous studies investigated p53 mutational
status by immunohistochemical detection of the p53 pro-
tein [5,6,11,12]. The gold standard elective surgery for UC
with colitic cancer or high-grade dysplasia is proctocolect-
omy with ileal pouch anastomosis because synchronous
and metachronous multiple cancers develop at high rates.
However, we performed partial resection of the colon can-
cer in this UC case because the unaffected UC mucosa did
not develop p53 mutations, nor was it likely to develop
dysplasia or colitic cancer. It was an important issue that
his UC had been well controlled with medicine. Among
patients with moderate or worse inflammation of colitis
that requires aggressive medical treatment, total proctoco-
lectomy should be performed even in patients with spor-
adic cancer [3]. Also, he had 3 months from the initial
diagnosis of UC to the operation of the cancer without pre-
vious history of UC. It could be a too short duration of col-
itis to develop colitic cancer. Recent review reported that
the risk for developing CRC increased with longer duration
of colitis, and CRC was rarely encountered in patients who
have had colitis for less than 7 years [10].
Additionally, the differences in endoscopic, clinical, and
histological findings between colitic and sporadic cancer
have been investigated in previous studies, leading to thediagnosis of sporadic cancer [2,4]. The optimal proced-
ure for UC with sporadic cancer remains unknown. Re-
cent reports have shown the safety and efficiency of
polypectomy treatment for adenoma-like dysplastic le-
sions, sporadic adenomas, and flat neoplasias in UC
[14-16]. Uchino et al. have described that partial resec-
tion may be adequate compared with restorative proc-
tocolectomy in view of anal function and quality of life
[3]. We also support that partial resection is adequate
for sporadic cancer in UC with well-controlled UC and
shorter disease duration status.
GCAP was performed at 7 days after operation after
his general condition had improved. Leukocytapheresis
(LCAP) and GCAP therapies involve extracorporeal re-
moval of peripheral leukocytes with the aim of suppress-
ing harmful immunologic reactions in patients with
chronic inflammatory disease. In adults with active UC,
significant clinical improvement with LCAP and GCAP
has been reported, permitting reduction of the doses of
corticosteroids [17]. Ikeuchi et al. and Itabashi et al.
have reported the effectiveness and safety of periopera-
tive use of leukocytapheresis for postoperative complica-
tions [18,19].
Conclusions
We have reported, for the first time, that a partial resec-
tion was performed in a patient with sporadic cancer
with UC based on not only endoscopic, clinical, and
histological findings but also that the unaffected mucosa
did not detect p53 protein overexpression. In making
the decision regarding a surgical procedure in colorectal
cancer for patients with UC, we have to make a compre-
hensive evaluation based on the clinical, endoscopic, and
histological findings which include immunostaining re-
sults. Although false positive and negative results in the
analysis of p53 mutation status by immunostaining
could be observed, we indicate that the immunostaining
of p53 protein can be a useful marker.
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